Mutations in key epidermal growth factor receptor (EGFR) driver genes can affect downstream molecular networks and pathways, thereby influencing therapeutic response in NSCLC, and IPA causal network analysis revealed that the causal network of APEX1 was highly activated under the Ex19del mutation (Nishimura et al., 2020). Here, EGFR is linked to non-small cell lung carcinoma.